Pipeline

BioArctic’s portfolio has projects in several focus areas and in various phases from discovery through clinical development.

Alzheimer’s disease
Project
Lecanemab
Early Alzheimer's disease2
Partner
Eisai1
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
Lecanemab AHEAD 3-45
Preclinical (asymptomatic) Alzheimer's disease3
Partner
Eisai1
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
Lecanemab back-up
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
BAN1503 (PyroGlu Aβ)
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
BAN2802
Partner
Eisai
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
BAN2803 (PyroGlu Aβ with BT)
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
AD2603
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Alzheimer’s disease
Project
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory & Market
Lecanemab
Early Alzheimer's disease2
Eisai1
Lecanemab AHEAD 3-45
Preclinical (asymptomatic) Alzheimer's disease3
Eisai1
Lecanemab back-up
Eisai
BAN1503 (PyroGlu Aβ)
BAN2802
Eisai
BAN2803 (PyroGlu Aβ with BT)
AD2603
Parkinson’s disease
Project
Exidavnemab (BAN0805) (α-synuclein)
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Parkinson’s disease
Project
PD1601 (α-synuclein)
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Parkinson’s disease
Project
PD1602 (α-synuclein)
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Parkinson’s disease
Project
PD-BT2238 (α-synuclein with BT)
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Parkinson’s disease
Project
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory & Market
Exidavnemab (BAN0805) (α-synuclein)
PD1601 (α-synuclein)
PD1602 (α-synuclein)
PD-BT2238 (α-synuclein with BT)
Other CNS disorders
Project
Lecanemab
Down's syndrome4
Traumatic brain injury4
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Other CNS disorders
Project
ND3014 (TDP43)
ALS
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Other CNS disorders
Project
ND-BT3814 (TDP-43 with BT)
ALS
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Other CNS disorders
Project
GD-BT6822 (GCase with BT)
Gaucher disease
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Other CNS disorders
Project
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory & Market
Lecanemab
Down's syndrome4
Traumatic brain injury4
ND3014 (TDP43)
ALS
ND-BT3814 (TDP-43 with BT)
ALS
GD-BT6822 (GCase with BT)
Gaucher disease
Blood-brain barrier
Project
BrainTransporter™ (BT) technology platform
Research Preclinical Phase 1 Phase 2 Phase 3 Regulatory & Market
Blood-brain barrier
Project
Partner
Research
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory & Market
BrainTransporter™ (BT) technology platform

  1. Partner with Eisai for lecanemab for treatment of Alzheimer’s disease since 2007. Eisai entered partnership with Biogen regarding BAN2401 (lecanemab) in 2014
  2. Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease
  3. Normal cognitive function with intermediate or elevated levels of amyloid in the brain
  4. Dementia and cognitive impairment associated with Down’s syndrome and with traumatic brain injur